(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 156.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Liquidia's revenue in 2025 is $13,996,000.On average, 4 Wall Street analysts forecast LQDA's revenue for 2025 to be $3,756,121,077, with the lowest LQDA revenue forecast at $2,419,066,509, and the highest LQDA revenue forecast at $5,203,210,757. On average, 4 Wall Street analysts forecast LQDA's revenue for 2026 to be $12,066,075,148, with the lowest LQDA revenue forecast at $6,838,383,711, and the highest LQDA revenue forecast at $17,742,095,696.
In 2027, LQDA is forecast to generate $20,177,966,017 in revenue, with the lowest revenue forecast at $9,713,797,394 and the highest revenue forecast at $30,332,159,757.